Modification of clinical and laboratory status and its correction in patients with the featured clinical course of asthma

Abstract

This paper examines specific characteristics of changes in clinical and laboratory parameters associated with some clinical forms of asthma in the stages of exacerbation and remission and demonstrates the efficacy of differential immunotherapy in patients. The observations were made on 175 patients suffering from mixed, exogenous, and endogenous asthma, asthma and COPD overlap syndrome, and asthma accompanied by atopic dermatitis in exacerbation and remission; they received standard treatment, as well as its combination with hypoxen and sodium nucleinate. The study also involved 30 healthy, one-time donors. An evaluation was made of five clinical, 13 hematological, and 19 immune system parameters in patients before and after treatments by state-of-the-art techniques. The application of methods of mathematical analysis helped to identify laboratory markers for the disorders, determine targets for “correction,” and characterize the clinical and laboratory response to the differential treatment. It has been established that the severity of clinical and laboratory abnormalities depends on the pathogenesis, stage of COPD progression, and asthma sensitization; thus, the nature of immunopathology was shown to play a primary role. Quantitative laboratory indications have been determined for the selection of a type of immunomodulator based on inversion analysis of the key parameters of formulas for immune system correction.